FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Primo Lara

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
David C Smith; Matthew R Smith; Alexander I Spira; Sandy Srinivas; Christopher Sweeney; Ulka Nitin Vaishampayan; Nicholas J Vogelzang; Aaron L Weitzman; Paul G Corn; Aymen A Elfiky; Michael S Gordon; Naomi B Haas; Andrea L Harzstark; Primo Lara; Chia-Chi Lin; Christopher Logothetis; Christian Scheffold; Patrick Schöffski; Avishay Sella; Eric J Small; Maha Hussain
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
Philip C Mack; David R Gandara; Primo Lara
Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approach.
Thomas J Semrad; Derick H Lau; Chong-Xian Pan; Laurel Beckett; Courtney Eddings; David R Gandara; Primo Lara
Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Primo Lara (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: David C Smith; Matthew R Smith; Alexander I Spira; Sandy Srinivas; Christopher Sweeney; Ulka Nitin Vaishampayan; Nicholas J Vogelzang; Aaron L Weitzman; Paul G Corn; Aymen A Elfiky; Michael S Gordon; Naomi B Haas; Andrea L Harzstark; Primo Lara; Chia-Chi Lin; Christopher Logothetis; Christian Scheffold; Patrick Schöffski; Avishay Sella; Eric J Small; Maha Hussain
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(4):412-9.
2012: Philip C Mack; David R Gandara; Primo Lara
Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approach.
Expert review of anticancer therapy 2012;12(12):1591-6.
2012: Thomas J Semrad; Derick H Lau; Chong-Xian Pan; Laurel Beckett; Courtney Eddings; David R Gandara; Primo Lara
Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors.
Investigational new drugs 2012;30(5):2001-7.
2012: David R Gandara; Neal Goodwin; Karen Kelly; Primo Lara; Tianhong Li; Philip C Mack; Suzanne Miyamoto; Laurel Beckett; Mary W Redman
Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity.
Clinical lung cancer 2012;13(5):321-5.
2012: Hongyong Zhang; Xiaobing Wang; Olulanu H Aina; James A Bassuk; Ralph W deVere White; Christopher P Evans; Paul Henderson; Kit S Lam; Primo Lara; Chong-Xian Pan
Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach.
Urologic oncology 2012;30(5):635-45.
2012: Derek Shek; Benjamin Tomlinson; Monica Brown; Ann Brunson; Chong-Xian Pan; Primo Lara
Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients.
Clinical genitourinary cancer 2012;10(2):93-8.
2012: Brian Hu; Primo Lara; Christopher P Evans
Defining an individualized treatment strategy for metastatic renal cancer.
The Urologic clinics of North America 2012;39(2):233-49, vii.
2012: Tianhong Li; Thehang Luu; Philip C Mack; Kim A Margolin; Sanjiv S Agarwala; Scott D Christensen; Paul H Frankel; Primo Lara; David R Gandara
A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.
Investigational new drugs 2012;30(2):741-8.
2012: Tzu-Yin Lin; Juntao Luo; Hongyong Zhang; Ralph W deVere White; Tingjuan Gao; Kit S Lam; Primo Lara; Yuanpei Li; Chong-Xian Pan
Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer.
International journal of nanomedicine 2012;7():2793-804.
2012: Sara H Javid; Primo Lara; Carol M Moinpour; Joseph M Unger; Pamela A Williams; Antoinette J Wozniak; J Wendall Goodwin; Carolyn C Gotay; Julie R Gralow; Laura F Hutchins; Kathy S Albain
A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316).
The oncologist 2012;17(9):1180-90.
2012: James S Chang; Primo Lara; Chong-Xian Pan
Progress in personalizing chemotherapy for bladder cancer.
Advances in urology 2012;2012():364919.
2012: Primo Lara; M W Redman
The hazards of randomized phase II trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(1):7-9.
2012: Maria C Pietanza; Nandagopal Vrindavanam; Heather A Wakelee; Ronald H Yanagihara; John Cho; Naveed Mahfooz Chowhan; Roel Funke; Shirish M Gadgeel; Primo Lara; Thomas James Lynch; Ben Mitchell; Nathan A Pennell; Vincent A Miller
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(1):219-26.
2012: William S Holland; Danielle C Chinn; Jose E Pietri; Philip C Mack; Clifford G Tepper; David R Gandara; Primo Lara
Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.
Cancer chemotherapy and pharmacology 2012;69(1):185-94.
2011: Randeep Sangha; Laurel Beckett; Angela M Davies; Paul J Hesketh; Primo Lara; Derick H Lau; Tianhong Li; Philip C Mack; Natasha Perkins; David R Gandara
Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(12):2112-9.
2011: Suresh S Ramalingam; Karen Reckamp; Ravi Salgia; Miguel Villalona-Calero; Everett E Vokes; John J Wright; Chandra P Belani; Angela M Davies; Martin J Edelman; Barbara Gitlitz; Primo Lara; Jeffrey Longmate; David R Gandara
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(10):1741-5.
2011: Derek Shek; Przemyslaw Twardowski; Paul Frankel; David R Gandara; Jeff Longmate; Kim A Margolin; Chong-Xian Pan; David I Quinn; Primo Lara
A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma.
International journal of clinical oncology 2011;16(5):494-9.
2011: Karim Chamie; John M Boone; Christopher P Evans; Theresa Koppie; Eric A Kurzrock; Primo Lara; Mark S Litwin; Sandra L Wootton-Gorges; Ralph W deVere White
Secondary malignancies among nonseminomatous germ cell tumor cancer survivors.
Cancer 2011;117(18):4219-30.
2011: Primo Lara; György Losonczy; Mark J McKeage; Kazuhiko Nakagawa; Martin Reck; Istvan Albert; Jean-Yves Douillard; Xiaolin Fan; Abderrahim Fandi; Dae Seog Heo; Joachim von Pawel; Giorgio Scagliotti
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(22):2965-71.
2011: Thomas J Semrad; David R Gandara; Primo Lara
Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience.
Therapeutic advances in medical oncology 2011;3(2):95-100.
2011: Sacha I Rothschild; Oliver Gautschi; Primo Lara; Philip C Mack; David R Gandara
Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer.
Current opinion in oncology 2011;23(2):150-7.
2011: Primo Lara; Jeff Longmate; Karen Reckamp; Barbara Gitlitz; Athanassios Argiris; Suresh Ramalingam; Chandra P Belani; Philip C Mack; Derick H Lau; Mariana Koczywas; John J Wright; Frances A Shepherd; Natasha B Leighl; David R Gandara
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
Clinical lung cancer 2011;12(1):33-7.
2011: Allen M Chen; Primo Lara
Medical oncology: Chemoradiotherapy for NSCLC-does a 'standard' exist?
Nature reviews. Clinical oncology 2011;8(1):5-6.
2010: Primo Lara; Kari Chansky; Taro Shibata; Haruhiko Fukuda; Tomohide Tamura; John Crowley; Mary W Redman; Ronald Natale; Nagahiro Saijo; David R Gandara
Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124.
Cancer 2010;116(24):5710-5.
2010: David R Gandara; Peter Grimminger; Philip C Mack; Primo Lara; Tianhong Li; Peter V Danenberg; Kathleen D Danenberg
Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(12):1933-8.
2010: Sisi Wang; Hongyong Zhang; Michael Malfatti; Ralph de Vere White; Primo Lara; Kenneth Turteltaub; Paul Henderson; Chong-Xian Pan
Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells.
Chemical research in toxicology 2010;23(11):1653-5.
2010: Jennifer Marie Suga; Danh V Nguyen; Sandra M Mohammed; Monica Brown; Royce Calhoun; Ken Y Yoneda; David R Gandara; Primo Lara
Racial disparities on the use of invasive and noninvasive staging in patients with non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(11):1772-8.
2010: Przemyslaw Twardowski; Walter M Stadler; Paul Frankel; Primo Lara; Christopher Ruel; Gurkamal Chatta; Elisabeth Iljas Heath; David I Quinn; David R Gandara
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.
Urology 2010;76(4):923-6.
2010: Tanya B Dorff; Bryan Goldman; Jacek Pinski; Philip C Mack; Primo Lara; Peter J Van Veldhuizen; David I Quinn; Nicholas J Vogelzang; Ian M Thompson; Maha Hussain
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(11):3028-34.
2010: David R Gandara; Philip C Mack; Tianhong Li; Primo Lara; Roy S Herbst
[Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012].
Zhongguo fei ai za zhi = Chinese journal of lung cancer 2010;13(3):238-41.
2010: Tianhong Li; Primo Lara; Philip C Mack; Roman Perez-Soler; David R Gandara
Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer.
Current drug targets 2010;11(1):85-94.
2009: Philip C Mack; William S Holland; Rebekah A Burich; Randeep Sangha; Leslie J Solis; Yueju Li; Laurel Beckett; Primo Lara; Angela M Davies; David R Gandara
EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(12):1466-72.
2009: Michael S Gordon; Michael Hussey; Raymond B Nagle; Primo Lara; Philip C Mack; Janice Dutcher; Wolfram Samlowski; Joseph I Clark; David I Quinn; Chong-Xian Pan; David Crawford
Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(34):5788-93.
2009: David R Gandara; Philip C Mack; Tianhong Li; Primo Lara; Roy S Herbst
Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012.
Clinical lung cancer 2009;10(6):392-4.
2009: Peter J Van Veldhuizen; Joseph I Clark; Regina Gandour-Edwards; Michael Hussey; Marianne K Lange; Primo Lara; Philip C Mack; David E Crawford
A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.
American journal of clinical oncology 2009;32(5):453-9.
2009: Randeep Sangha; Primo Lara; Alex A Adjei; Paul Baas; Hak Choy; Laurie E Gaspar; Glenwood Goss; Nagahiro Saijo; Joan H Schiller; Everett E Vokes; David R Gandara
Cooperative group research endeavors in small-cell lung cancer: current and future directions.
Clinical lung cancer 2009;10(5):322-30.
2009: David R Gandara; Tomoya Kawaguchi; John Crowley; James Moon; Kiyoyuki Furuse; Masaaki Kawahara; Satoshi Teramukai; Yuichiro Ohe; Kaoru Kubota; Stephen K Williamson; Oliver Gautschi; Heinz-Josef Lenz; howard mcleod; Primo Lara; Charles Arthur Coltman; Masahiro Fukuoka; Nagahiro Saijo; Masanori Fukushima; Philip C Mack
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(21):3540-6.
2009: Angela M Davies; Cheryl Ho; Laurel Beckett; Derick H Lau; Sidney A Scudder; Primo Lara; Natasha Perkins; David R Gandara
Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(7):862-8.
2009: Quynh-Thu Le; James Moon; Mary Redman; Stephen K Williamson; Primo Lara; Zelanna Goldberg; Laurie E Gaspar; John J Crowley; Dennis F Moore; David R Gandara
Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(18):3014-9.
2009: Ralph W deVere White; Primo Lara; Bryan Goldman; Cathy M Tangen; David C Smith; David P Wood Jr; Maha Hussain; E David Crawford
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).
The Journal of urology 2009;181(6):2476-80; discussion 2480-1.
2009: Primo Lara; Ronald Natale; John Crowley; Heinz-Josef Lenz; Mary W Redman; Jane E Carleton; James Jett; Corey J Langer; J Philip Kuebler; Shaker R Dakhil; Kari Chansky; David R Gandara
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(15):2530-5.
2009: David R Gandara; Primo Lara; Philip C Mack; Giorgio Scagliotti
Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making.
Clinical lung cancer 2009;10(3):148-50.
2009: Phillip R Purnell; Philip C Mack; Clifford G Tepper; Christopher P Evans; Tim P Green; Paul H Gumerlock; Primo Lara; David R Gandara; Hsing-Jien Kung; Oliver Gautschi
The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(4):448-54.
2009: Gigi Chen; Minh Huynh; Lou Fehrenbacher; Howard West; Primo Lara; Leonid L Yavorkovsky; Michael Russin; Desiree Goldstein; David R Gandara; Derick H Lau
Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(9):1401-4.
2009: Randeep Sangha; Primo Lara; Philip C Mack; David R Gandara
Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
Current opinion in oncology 2009;21(2):116-23.
2009: Primo Lara; Jeff Longmate; Christopher P Evans; David I Quinn; Przemyslaw Twardowski; Gurkamal Chatta; Edwin Posadas; Walter Stadler; David R Gandara
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
Anti-cancer drugs 2009;20(3):179-84.
2009: Primo Lara; Catherine M Tangen; Sarah J Conlon; Robert C Flanigan; E David Crawford
Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949.
The Journal of urology 2009;181(2):512-6; discussion 516-7.
2009: Eric Cheung; Jacek Pinski; Tanya B Dorff; Susan Groshen; David I Quinn; Charles Patrick Reynolds; Barry J Maurer; Primo Lara; Denice D Tsao-Wei; Przemyslaw Twardowski; Gurkamal Chatta; Mark McNamara; David R Gandara
Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial.
Clinical genitourinary cancer 2009;7(1):43-50.
2009: Angela M Davies; Kari Chansky; Primo Lara; Paul H Gumerlock; John Crowley; Kathy S Albain; Stanley J Vogel; David R Gandara
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(1):87-92.
2008: Philip C Mack; Mary W Redman; Kari Chansky; Stephen K Williamson; Nichole C Farneth; Primo Lara; Wilbur A Franklin; Quynh-Thu Le; John J Crowley; David R Gandara
Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(29):4771-6.
2008: David R Gandara; Primo Lara; Ronald Natale; Chandra P Belani
Progress in small-cell lung cancer: the lowest common denominator.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(26):4236-8.
2008: Tomasz M Beer; Bryan Goldman; Timothy W Synold; Christopher W Ryan; Lakshmi S Vasist; Peter J Van Veldhuizen; Shaker R Dakhil; Primo Lara; Anibal Drelichman; Maha Hussain; E David Crawford
Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.
Clinical genitourinary cancer 2008;6(2):103-9.
2008: Michelle L Ramírez; Eric C Nelson; Ralph W deVere White; Primo Lara; Christopher P Evans
Current applications for prostate-specific antigen doubling time.
European urology 2008;54(2):291-300.
2008: Karen G Chee; Danh V Nguyen; Monica Brown; David R Gandara; Ted Wun; Primo Lara
Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited.
Archives of internal medicine 2008;168(14):1541-9.
2008: Derick H Lau; Jewel Johl; Minh Huynh; Angela Davies; Michael Tanaka; Primo Lara; David R Gandara
Population-based phase I trial of irinotecan and epirubicin.
American journal of clinical oncology 2008;31(3):226-30.
2008: Primo Lara; Suresh S Ramalingam
Monoclonal antibodies versus tyrosine kinase inhibitors concurrent with chemotherapy in non-small-cell lung cancer: exploring divergent results.
Clinical lung cancer 2008;9(3):141-3.
2008: Oliver Gautschi; Clifford G Tepper; Phillip R Purnell; Yoshihiro Izumiya; Christopher P Evans; Tim P Green; Pierre Y Desprez; Primo Lara; David R Gandara; Philip C Mack; Hsing-Jien Kung
Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer.
Cancer research 2008;68(7):2250-8.
2008: Oliver Gautschi; Jim Heighway; Philip C Mack; Phillip R Purnell; Primo Lara; David R Gandara
Aurora kinases as anticancer drug targets.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(6):1639-48.
2008: Primo Lara; Mary W Redman; Karen Kelly; Martin J Edelman; Stephen K Williamson; John J Crowley; David R Gandara
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(3):463-7.
2008: Randeep Sangha; Primo Lara; Philip C Mack; David R Gandara
Targeted therapies in non-small-cell lung cancer: a paradigm in evolution.
Clinical lung cancer 2008;9 Suppl 3():S90-1.
2008: Mark Levandovsky; Danielle Harvey; Primo Lara; Ted Wun
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients.
Journal of hematology & oncology 2008;1():23.
2008: Angela M Davies; Christopher Ruel; Primo Lara; Derick H Lau; Paul H Gumerlock; Richard J Bold; Stephen Shibata; Heinz-Josef Lenz; David P Schenkein; David R Gandara
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(1):68-74.
2008: Ari Umutyan; Christine Chiechi; Laurel Beckett; Debora A Paterniti; Corinne Turrell; David R Gandara; Sharon W Davis; Ted Wun; Moon S Chen; Primo Lara
Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign.
Cancer 2008;112(1):212-9.
2007: Karen G Chee; Jeff Longmate; David I Quinn; Gurkamal Chatta; Jacek Pinski; Przemyslaw Twardowski; Chong-Xian Pan; Angelo Cambio; Christopher P Evans; David R Gandara; Primo Lara
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.
Clinical genitourinary cancer 2007;5(7):433-7.
2007: Angela M Davies; Cheryl Ho; Alex S Metzger; Laurel Beckett; Scott Christensen; Michael Tanaka; Primo Lara; Derick H Lau; David R Gandara
Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(12):1112-6.
2007: Christopher M Mahaffey; Angela M Davies; Primo Lara; Brandi Pryde; William Holland; Philip C Mack; Paul H Gumerlock; David R Gandara
Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.
Clinical lung cancer 2007;8(9):548-53.
2007: Ruth L Vinall; Kimberley Hwa; Paramita M Ghosh; Chong-Xian Pan; Primo Lara; Ralph W deVere White
Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(20):6204-16.
2007: Kim Margolin; Timothy W Synold; Primo Lara; Paul Frankel; Simon F Lacey; David I Quinn; Tracey Baratta; Janice P Dutcher; Bixin Xi; Don J Diamond; David R Gandara
Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium.
Journal of cancer research and clinical oncology 2007;133(10):705-11.
2007: Akhil Wadhera; Emanual Maverakis; Nicholas Mitsiades; Primo Lara; Maxwell A Fung; Peter J Lynch
Thymoma-associated multiorgan autoimmunity: a graft-versus-host-like disease.
Journal of the American Academy of Dermatology 2007;57(4):683-9.
2007: Johan Vansteenkiste; Primo Lara; Thierry Le Chevalier; Jean-Luc Breton; Philip Bonomi; Alan B Sandler; Mark A Socinski; Catherine Delbaldo; Brent McHenry; David Lebwohl; Ronald Peck; Martin J Edelman; Mark Edelman
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3448-55.
2007: Angela M Davies; Primo Lara; Philip C Mack; David R Gandara
Incorporating bortezomib into the treatment of lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 2):s4647-51.
2007: Christopher W Ryan; Bryan H Goldman; Primo Lara; Philip C Mack; Tomasz M Beer; Catherine M Tangen; Dianne Lemmon; Chong-Xian Pan; Harry A Drabkin; E David Crawford
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(22):3296-301.
2007: Eric C Nelson; Christopher P Evans; Chong-Xian Pan; Primo Lara
Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications.
World journal of urology 2007;25(4):393-9.
2007: Angela M Davies; Cheryl Ho; Paul J Hesketh; Laurel Beckett; Primo Lara; Derick H Lau; David R Gandara
Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study.
Investigational new drugs 2007;25(4):351-5.
2007: Primo Lara; Angela M Davies
Optimizing targeted therapy in patients with lung cancer with a performance status of 2.
Clinical lung cancer 2007;8(7):410-1.
2007: Maha Hussain; Gary R MacVicar; Daniel P Petrylak; Rodney L Dunn; Ulka Nitin Vaishampayan; Primo Lara; Gurkamal S Chatta; David M Nanus; L Michael Glode; Donald L Trump; Helen Chen; David C Smith
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(16):2218-24.
2007: Eric C Nelson; Christopher P Evans; Primo Lara
Renal cell carcinoma: current status and emerging therapies.
Cancer treatment reviews 2007;33(3):299-313.
2007: David R Gandara; Angela M Davies; Oliver Gautschi; Philip C Mack; Derick H Lau; Primo Lara; Fred R Hirsch
Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies.
Clinical lung cancer 2007;8 Suppl 2():S61-7.
2007: Eric C Nelson; Angelo J Cambio; Joy C Yang; Primo Lara; Christopher P Evans
Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation.
Nature clinical practice. Urology 2007;4(2):82-94.
2007: Robert J Motzer; Craig J Nichols; Kim A Margolin; Jennifer Bacik; Paul G Richardson; Nicholas J Vogelzang; Dean F Bajorin; Primo Lara; Lawrence Einhorn; Madhu Mazumdar; George J Bosl
Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(3):247-56.
2007: E C Nelson; Christopher P Evans; Philip C Mack; Ralph W deVere White; Primo Lara
Inhibition of Akt pathways in the treatment of prostate cancer.
Prostate cancer and prostatic diseases 2007;10(4):331-9.
2007: E C Nelson; Angelo Cambio; J C Yang; Joon-ha Ok; Primo Lara; Christopher P Evans
Clinical implications of neuroendocrine differentiation in prostate cancer.
Prostate cancer and prostatic diseases 2007;10(1):6-14.
2006: Chong-Xian Pan; Hongyong Zhang; Primo Lara; Liang Cheng
Small-cell carcinoma of the urinary bladder: diagnosis and management.
Expert review of anticancer therapy 2006;6(12):1707-13.
2006: Primo Lara; Kari Chansky; Angela M Davies; Wilbur A Franklin; Paul H Gumerlock; Perry P Guaglianone; James N Atkins; Nichole Farneth; Philip C Mack; John J Crowley; David R Gandara
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(9):996-1001.
2006: David R Gandara; Kari Chansky; Kathy S Albain; Laurie E Gaspar; Primo Lara; Karen Kelly; John Crowley; Robert Livingston
Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504).
Clinical lung cancer 2006;8(2):116-21.
2006: Oliver Gautschi; Philip C Mack; Angela M Davies; Primo Lara; David R Gandara
Aurora kinase inhibitors: a new class of targeted drugs in cancer.
Clinical lung cancer 2006;8(2):93-8.
2006: Primo Lara; Ralph W deVere White
Accrual issues in genitourinary cancer clinical trials.
Urologic oncology 2006;24(5):379-83.
2006: Donna L Berry; Carol M Moinpour; Caroline S Jiang; Donna Pauler Ankerst; Daniel P Petrylak; Lynne V Vinson; Primo Lara; Sharon Jones; Mary Ellen Taplin; Patrick A Burch; Maha Hussain; E David Crawford
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(18):2828-35.
2006: Angela M Davies; Cheryl Ho; Primo Lara; Philip C Mack; Paul H Gumerlock; David R Gandara
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.
Clinical lung cancer 2006;7(6):385-8.
2006: Cheryl Ho; Angela M Davies; Primo Lara; David R Gandara
Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options.
Clinical lung cancer 2006;7 Suppl 4():S118-25.
2006: Daniel P Petrylak; Donna Pauler Ankerst; Caroline S Jiang; Catherine M Tangen; Maha Hussain; Primo Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
Journal of the National Cancer Institute 2006;98(8):516-21.
2006: Primo Lara; David R Gandara; Ronald B Natale
Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.
Clinical lung cancer 2006;7(5):353-6.
2006: Primo Lara; Walter M Stadler; Jeff Longmate; David I Quinn; Jason Wexler; Marta D Van Loan; Przemyslaw Twardowski; Paul H Gumerlock; Nicholas J Vogelzang; Everett E Vokes; Heinz-Josef Lenz; James Doroshow; David R Gandara
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(5):1556-63.
2006: Primo Lara; Mariana Koczywas; David I Quinn; Heinz-Josef Lenz; Angela M Davies; Derick H Lau; Paul H Gumerlock; Jeff Longmate; James Doroshow; David P Schenkein; Oscar Kashala; David R Gandara
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(2):126-34.
2006: Primo Lara
Molecular selection for therapy of patients with non-small-cell lung cancer and impaired performance status: has the time come?
Clinical lung cancer 2006;7(4):232-4.
2005: Primo Lara; Debora A Paterniti; Christine Chiechi; Corinne Turrell; Claudia Morain; Nora Horan; Lisa Montell; Jose Gonzalez; Sharon Davis; Ari Umutyan; Cynthia L Martel; David R Gandara; Ted Wun; Laurel Beckett; Moon S Chen
Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9282-9.
2005: Stephen K Williamson; John J Crowley; Primo Lara; Jason McCoy; Derick H Lau; Robert W Tucker; Glenn M Mills; David R Gandara
Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9097-104.
2005: Debora A Paterniti; Moon S Chen; Christine Chiechi; Laurel Beckett; Nora Horan; Corinne Turrell; Ligaya Smith; Claudia Morain; Lisa Montell; Jose Luis Gonzalez; Sharon Davis; Primo Lara
Asian Americans and cancer clinical trials: a mixed-methods approach to understanding awareness and experience.
Cancer 2005;104(12 Suppl):3015-24.
2005: James R Rigas; Primo Lara
Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2005;50 Suppl 2():S17-24.
2005: David R Gandara; Eric Vallières; Laurie E Gaspar; Karen Kelly; Kathy S Albain; Roy S Herbst; Primo Lara; Philip C Mack; Paul H Gumerlock; John J Crowley
Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy.
Clinical lung cancer 2005;7 Suppl 3():S93-7.
2005: Maha Hussain; Catherine M Tangen; Primo Lara; Ulka Nitin Vaishampayan; Daniel P Petrylak; A Dimitrios Colevas; Wael A Sakr; E David Crawford
Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(34):8724-9.
2005: Primo Lara; Richard J Bold; Philip C Mack; Angela M Davies; Paul H Gumerlock; David R Gandara
Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.
Clinical lung cancer 2005;7 Suppl 2():S67-71.
2005: Angela M Davies; Primo Lara; Philip C Mack; Paul H Gumerlock; Richard J Bold; David R Gandara
Bortezomib-based combinations in the treatment of non-small-cell lung cancer.
Clinical lung cancer 2005;7 Suppl 2():S59-63.
2005: Karen Giselle Chee; Angelo Cambio; Primo Lara
Recent developments in advanced urothelial cancer.
Current opinion in urology 2005;15(5):342-9.
2005: Joon-ha Ok; Angelo Cambio; Primo Lara; Christopher P Evans
Is the use of anything but MVAC justified in the evidence-based medicine era?
Current opinion in urology 2005;15(5):312-4.
2005: Carol M Richman; Sally J DeNardo; Robert T O'Donnell; Aina Yuan; Sui Shen; Desiree S Goldstein; Joseph M Tuscano; Ted Wun; Helen K Chew; Primo Lara; David L Kukis; Arutselvan Natarajan; Claude F Meares; Kathleen R Lamborn; Gerald L DeNardo
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5920-7.
2005: Melinda M Mortenson; Michael G Schlieman; Subbulakshmi Virudachalam; Primo Lara; David R Gandara; Angela M Davies; Richard J Bold
Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2005;49(2):163-70.
2005: David R Gandara; Samir Narayan; Primo Lara; Zelanna Goldberg; Angela Davies; Derick H Lau; Philip C Mack; Paul H Gumerlock; Srinivasan Vijayakumar
Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13 Pt 2):5057s-5062s.
2005: Peter J Van Veldhuizen; James R Faulkner; Primo Lara; Paul H Gumerlock; J Wendall Goodwin; Shaker R Dakhil; Howard M Gross; Robert C Flanigan; E David Crawford
A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.
Cancer chemotherapy and pharmacology 2005;56(1):39-45.
2005: Primo Lara; Philip C Mack; Timothy W Synold; Paul Frankel; Jeff Longmate; Paul H Gumerlock; James Doroshow; David R Gandara
The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4444-50.
2005: Primo Lara; Lisa Y Law; John J Wright; Paul Frankel; Przemyslaw Twardowski; Heinz-Josef Lenz; Derick H Lau; Tomoya Kawaguchi; Paul H Gumerlock; James Doroshow; David R Gandara
Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.
Anti-cancer drugs 2005;16(3):317-21.
2004: Primo Lara; Przemyslaw Twardowski; David I Quinn
Angiogenesis-targeted therapies in prostate cancer.
Clinical prostate cancer 2004;3(3):165-73.
2004: Daniel P Petrylak; Catherine M Tangen; Maha Hussain; Primo Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol M Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
The New England journal of medicine 2004;351(15):1513-20.
2004: Cynthia L Martel; Yueju Li; Laurel Beckett; Helen K Chew; Scott Christensen; Angela Davies; Kit S Lam; Derick H Lau; Frederick J Meyers; Robert T O'Donnell; Carol M Richman; Sidney Scudder; Michael Tanaka; Joseph M Tuscano; Jeanna Welborn; Ted Wun; David R Gandara; Primo Lara
An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California.
Cancer journal (Sudbury, Mass.) 2004;10(5):294-300.
2004: Primo Lara; Paul H Gumerlock; Philip C Mack; Derick H Lau; Regina Gandour-Edwards; Martin J Edelman; Kathy S Albain; Lisa Y Law; Jeff Longmate; Paul Frankel; Gayatri P Reddy; Valerie Israel; James Doroshow; David R Gandara
Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.
Clinical lung cancer 2004;6(2):102-7.
2004: Primo Lara; Karen Giselle Chee; Jeff Longmate; Christopher Ruel; Frederick J Meyers; Carl R Gray; Regina Gandour-Edwards; Paul H Gumerlock; Przemyslaw Twardowski; James Doroshow; David R Gandara
Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
Cancer 2004;100(10):2125-31.
2004: Angela M Davies; Primo Lara; Derick H Lau; David R Gandara
Treatment of extensive small cell lung cancer.
Hematology/oncology clinics of North America 2004;18(2):373-85.
2004: Angela M Davies; Philip C Mack; Primo Lara; Derick H Lau; Kathleen Danenberg; Paul H Gumerlock; David R Gandara
Predictive molecular markers: has the time come for routine use in lung cancer?
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2(2):125-31.
2004: Primo Lara; Angela M Davies; Philip C Mack; Melinda M Mortenson; Richard J Bold; Paul H Gumerlock; David R Gandara
Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.
Seminars in oncology 2004;31(1 Suppl 1):40-6.
2004: Glenn Liu; David R Gandara; Primo Lara; Derek Raghavan; James Doroshow; Przemyslaw Twardowski; Philip W Kantoff; William K Oh; KyungMann Kim; George Wilding
A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(3):924-8.
2004: Primo Lara; Luko Laptalo; Jeff Longmate; Derick H Lau; Regina Gandour-Edwards; Paul H Gumerlock; James Doroshow; David R Gandara
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
Clinical lung cancer 2004;5(4):231-6.
2004: Primo Lara; Frederick J Meyers; Lisa Y Law; Nancy A Dawson; Joan Houston; Ignacio Lauder; Martin J Edelman
Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma.
Cancer 2004;100(1):82-8.
2003: Peter F Roberts; Michaela Straznicka; Primo Lara; Derick H Lau; David M Follette; David R Gandara; John R Benfield
Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved.
The Journal of thoracic and cardiovascular surgery 2003;126(5):1597-602.
2003: Primo Lara; David I Quinn; Kim Margolin; Frederick J Meyers; Jeff Longmate; Paul Frankel; Philip C Mack; Corinne Turrell; Peter Valk; Jyotsna Rao; Penelope Buckley; Ted Wun; Robert C Gosselin; Irina Galvin; Paul H Gumerlock; Heinz-Josef Lenz; James Doroshow; David R Gandara
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(13):4772-81.
2003: Primo Lara; Paul Frankel; Philip C Mack; Paul H Gumerlock; Irina Galvin; Cynthia L Martel; Jeff Longmate; James Doroshow; Heinz-Josef Lenz; Derick H Lau; David R Gandara
Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(12):4356-62.
2003: Sally J DeNardo; Gerald L DeNardo; Aina Yuan; Carol M Richman; Robert T O'Donnell; Primo Lara; David L Kukis; Arutselvan Natarajan; Kathleen R Lamborn; Frederik Jacobs; Christine L Hartmann Siantar
Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 2):3938S-44S.
2003: Philip C Mack; Angela M Davies; Primo Lara; Paul H Gumerlock; David R Gandara
Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.
Lung cancer (Amsterdam, Netherlands) 2003;41 Suppl 1():S89-96.
2003: Carolyn A Wild; Stephen E Wang; David R Gandara; Primo Lara; Frederick J Meyers; Michael Tanaka; Joan Houston; Jun Lauder; Derick H Lau
Population-based maximum tolerated dose of irinotecan and carboplatin.
Oncology (Williston Park, N.Y.) 2003;17(7 Suppl 7):11-6.
2003: Cynthia L Martel; Paul H Gumerlock; Frederick J Meyers; Primo Lara
Current strategies in the management of hormone refractory prostate cancer.
Cancer treatment reviews 2003;29(3):171-87.
2003: David R Gandara; Kari Chansky; Kathy S Albain; Bryan R Leigh; Laurie E Gaspar; Primo Lara; Howard Burris; Paul H Gumerlock; J Philip Kuebler; James Bearden; John Crowley; Robert Livingston
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10):2004-10.
2003: Philip C Mack; David R Gandara; Alvin H Lau; Primo Lara; Martin J Edelman; Paul H Gumerlock
Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma.
Cancer chemotherapy and pharmacology 2003;51(4):337-48.
2003: Angela M Davies; Primo Lara; Philip C Mack; David R Gandara
Docetaxel in non-small cell lung cancer: a review.
Expert opinion on pharmacotherapy 2003;4(4):553-65.
2003: Cynthia L Martel; Primo Lara
Renal cell carcinoma: current status and future directions.
Critical reviews in oncology/hematology 2003;45(2):177-90.
2003: Angela M Davies; David R Gandara; Primo Lara; Philip C Mack; Derick H Lau; Paul H Gumerlock
Antisense oligonucleotides in the treatment of non-small-cell lung cancer.
Clinical lung cancer 2003;4 Suppl 2():S68-73.
2003: Primo Lara
Adjuvant therapy in completely resected malignant thymoma.
Cancer investigation 2003;21(5):815-6.
2003: Nelson Lim; Primo Lara; Derick H Lau; Martin J Edelman; Michael Tanaka; Ghassan al-Jazayrly; Joan Houston; Ignacio Lauder; David R Gandara
Phase I trial of gemcitabine and paclitaxel in advanced solid tumors.
Cancer investigation 2003;21(1):7-13.
2002: Regina Gandour-Edwards; Primo Lara; Ann K Folkins; Janine M LaSalle; Laurel Beckett; Yueju Li; Frederick J Meyers; Ralph W deVere White
Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Cancer 2002;95(5):1009-15.
2002: Stephen E Wang; Primo Lara; Angie Lee-Ow; Jeanne Reed; Lori R Wang; Patti Palmer; Joseph M Tuscano; Carol M Richman; Laurel Beckett; Ted Wun
Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial.
American journal of hematology 2002;70(3):191-4.
2002: Angela Davies; David R Gandara; Primo Lara; Zelanna Goldberg; Peter Roberts; Derick H Lau
Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer.
Seminars in oncology 2002;29(3 Suppl 12):10-6.
2002: Primo Lara; Frederick J Meyers; Carl R Gray; Regina Gandour-Edwards; Paul H Gumerlock; Caren Kauderer; Garrett Tichauer; Przemyslaw Twardowski; James Doroshow; David R Gandara
HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial.
Cancer 2002;94(10):2584-9.
2002: Primo Lara; Zelanna Goldberg; Angela Davies; Derick H Lau; David R Gandara
Concurrent chemoradiation strategies in the management of unresectable stage III non-small-cell lung cancer.
Clinical lung cancer 2002;3 Suppl 2():S42-8.
2002: Primo Lara; Derick H Lau; David R Gandara
Non-small-cell lung cancer progression after first-line chemotherapy.
Current treatment options in oncology 2002;3(1):53-8.
2002: David R Gandara; Primo Lara; Zelanna Goldberg; Quynh T Le; Philip C Mack; Derick H Lau; Paul H Gumerlock
Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia.
Seminars in oncology 2002;29(1 Suppl 4):102-9.
2002: Justin Quock; Gilland Dea; Michael Tanaka; David R Gandara; Primo Lara; Derick H Lau
Premedication strategy for weekly paclitaxel.
Cancer investigation 2002;20(5-6):666-72.
2001: David R Gandara; Primo Lara; Derick H Lau; Philip C Mack; Paul H Gumerlock
Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach.
Lung cancer (Amsterdam, Netherlands) 2001;34 Suppl 3():S75-80.
2001: H L Liu; Regina Gandour-Edwards; Primo Lara; Ralph W deVere White; Janine M LaSalle
Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
Cancer journal (Sudbury, Mass.) 2001;7(5):395-403.
2001: Primo Lara; David R Gandara; Jeff Longmate; Paul H Gumerlock; Derick H Lau; Martin J Edelman; Regina Gandour-Edwards; Philip C Mack; Valerie Israel; James Raschko; Paul Frankel; E A Perez; Heinz-Josef Lenz; James Doroshow
Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial.
Cancer chemotherapy and pharmacology 2001;48(1):22-8.
2001: Martin J Edelman; David R Gandara; Derick H Lau; Primo Lara; Ignacio Lauder; D Tracy
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel.
Cancer 2001;92(1):146-52.
2001: David R Gandara; Primo Lara; Zelanna Goldberg; Derick H Lau
Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non--small cell lung cancer: focus on docetaxel.
Seminars in oncology 2001;28(3 Suppl 9):26-32.
2001: Robert T O'Donnell; Sally J DeNardo; Aina Yuan; Sui Shen; Carol M Richman; Primo Lara; I J Griffith; Desiree S Goldstein; David L Kukis; G S Martinez; Gary R Mirick; Gerald L DeNardo; Frederick J Meyers
Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1561-8.
2001: Primo Lara; R Higdon; N Lim; K Kwan; M Tanaka; Derick H Lau; Ted Wun; Jeanna Welborn; Frederick J Meyers; S Christensen; Robert T O'Donnell; Carol M Richman; Sidney Scudder; Joseph M Tuscano; David R Gandara; Kit S Lam
Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1728-33.
2001: David R Gandara; Martin J Edelman; Primo Lara; Derick H Lau
Gemcitabine in combination with new platinum compounds: an update.
Oncology (Williston Park, N.Y.) 2001;15(3 Suppl 6):13-7.
2001: David R Gandara; Primo Lara; Zelanna Goldberg; P Roberts; Derick H Lau
Neoadjuvant therapy for non-small cell lung cancer.
Anti-cancer drugs 2001;12 Suppl 1():S5-9.
2001: Derick H Lau; Bryan R Leigh; David R Gandara; Martin J Edelman; R Morgan; V Israel; Primo Lara; R Wilder; J Ryu; James Doroshow
Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(2):442-7.
2000: David R Gandara; Martin J Edelman; Primo Lara; P Roberts; Bryan R Leigh
Evolution of combined modality therapy for stage III non-small-cell lung cancer.
Oncology (Williston Park, N.Y.) 2000;14(7 Suppl 5):35-41.
2000: David R Gandara; Derick H Lau; Primo Lara; Martin J Edelman
Gemcitabine/carboplatin combination regimens: importance of dose schedule.
Oncology (Williston Park, N.Y.) 2000;14(7 Suppl 4):26-30.
2000: Primo Lara
Malignant thymoma: current status and future directions.
Cancer treatment reviews 2000;26(2):127-31.
1999: Primo Lara; Hsing-Jien Kung; Paul H Gumerlock; Frederick J Meyers
Molecular biology of prostate carcinogenesis.
Critical reviews in oncology/hematology 1999;32(3):197-208.
1999: Primo Lara; T L Coe; H Zhou; L Fernando; Paul V Holland; Ted Wun
Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
The American journal of medicine 1999;107(6):573-9.
1999: Primo Lara; Frederick J Meyers
Treatment options in androgen-independent prostate cancer.
Cancer investigation 1999;17(2):137-44.
1998: Frederick J Meyers; D Lew; Primo Lara; S Williamson; E Marshall; S P Balcerzak; Saul E Rivkin; Wolfram E Samlowski; E D Crawford
Phase II trial of edatrexate in relapsed or refractory germ cell tumors: a Southwest Oncology Group study (SWOG 9124).
Investigational new drugs 1998;16(4):347-51.
1998: Primo Lara; David R Gandara; G T Wurz; Derick H Lau; M Uhrich; Corinne Turrell; James Raschko; Martin J Edelman; Timothy W Synold; James Doroshow; Franco Muggia; E A Perez; Michael W DeGregorio
High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically.
Cancer chemotherapy and pharmacology 1998;42(6):504-8.
1997: Primo Lara; E Hearn; B Leigh
Neovaginal malignant melanoma following surgery and radiation for vulvar squamous cell carcinoma.
Gynecologic oncology 1997;65(3):520-2.
1996: Primo Lara; P D Bonomi; LP Faber
Retreatment of recurrent invasive thymoma with platinum, doxorubicin, and cyclophosphamide.
Chest 1996;110(4):1115-7.